Breakthrough with cancer vaccine
Potential to treat a variety of blood cancers
Scientists are ready to trial a new cancer vaccine in humans following the successful outcome of their preclinical studies.
Symbolic imgae
Pixabay
The new vaccine was developed by a Mater Research team based at The Translational Research Institute in collaboration with The University of Queensland.
Lead Researcher Associate Professor Kristen Radford says the vaccine has the potential to treat a variety of blood cancers and malignancies and is a major breakthrough for cancer vaccinations.
"We are hoping this vaccine could be used to treat blood cancers, such as myeloid leukaemia, non-Hodgkin's lymphoma, multiple myeloma, and paediatric leukaemias, plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma," she said.
"Our new vaccine is comprised of human antibodies fused with tumour-specific protein, and we are investigating its capacity to target human cells while activating the memory of the tumour cells."
Other news from the department science
